
KMT2A and NPM1 CT45 Clustering
study
WHO_2022
cluster
CT45A5
CT45A3
CT45A1
CT45A10
matrix_123
12
10
8
6
4
2
study
100LUMC_AML
BEAT_AML
LEUCEGENE_AML
TARGET_AML
TCGA_AML
WHO_2022
KMT2A
NPM1
cluster
High CT45
Low CT45


Five AML Cohorts NPM1 and MLL
Survival probability
1.00
0.75
0.50
0.25
0.00
p = 0.033
0
2.5
5
7.5
10
Time
CT45 cluster
cluster=High CT45
cluster=Low CT45


MLL patients
Survival probability
1.00
0.75
0.50
0.25
0.00
p = 0.095
0
2.5
5
7.5
10
Time
CT45 cluster
cluster=High CT45
cluster=Low CT45

Fisher’s p = 0.049; OR = 0.40 (95% CI 0.14–1.06)






Model: Surv ~ CT45 cluster + KMT2A subgroup + age (n = 74, events = 43)
CT45: High CT45
KMT2A subgroup: KMT2A−r Early
Age (per year)
TET21
FLT3ITD1
0.5
1.0
2.0
3.0
4.0
Hazard ratio (log scale)


CT45 cluster
Low CT45
High CT45
KMT2A_Subgroup: KMT2A−r Committed
KMT2A_Subgroup: KMT2A−r Early
Overall survival
1.00
0.75
0.50
0.25
0.00
p = 0.17
p = 0.45
0
2.5
5
7.5
10
Time (years)


ICAM1
ICAM2
ICAM3
NCAM1
KMT2A−r Committed
KMT2A−r Early
Expression
ns
ns
ns
ns
ns
*
ns
*
14
12
10
8
6
4
12.5
10.0
7.5
5.0
2.5
High CT45
Low CT45
cluster
High CT45
Low CT45